RCUS
Arcus Biosciences, Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.19Close
$2.3BMarket cap
$17.76 – $31.5752-week range
Nov 4, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 12 · weaker than 88% of stocks over 12 months
- Far from its high 42% below its 52-week high
- Results soon Nov 4, 2026, in 3 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
42%
1wk
down 1.9%
price change
1mo
down 29.6%
price change
12-month return
down 10%
market up 11% ·
its own down 21%
F-score
—
— Not assessed
Altman Z
0.59
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.6×
price / book
Earnings yield
down 17.9%
EBIT / enterprise value
Cheaper than
18%
of the market · expensive
Revenue growth
down 35%
year on year
EPS growth
—
latest quarter
Sales growth
up 312%
latest quarter · +325 pts
ROE
down 63%
return on equity
Free cash margin
down 1467%
-$484.0M FCF
D/E
0.16
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
7.9%
$1.44 a day · 2×ATR $15.30
RS
12 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 35.9% over the year, from 92m to 125m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 35.3% over the year, from $51.0M to $33.0M.
Last reported
Oct 21, 2026
Last shock
Oct 21, 2026-20% in one session2.8× volumeon results-5% since
Financials
- Net -1070%
- Free cash -1467%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $78.0M | $383.0M | $38.0M | $37.0M | $51.0M | $33.0M |
| Operating income | -$124.0M | $54.0M | -$280.0M | -$340.0M | -$330.0M | -$386.0M |
| Net income | -$123.0M | $53.0M | -$267.0M | -$307.0M | -$283.0M | -$353.0M |
| Net margin | -158% | 14% | -703% | -830% | -555% | -1070% |
| Earnings per share | -$2.24 | $0.72 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
| Free cash flow | $108.0M | -$282.0M | $432.0M | -$330.0M | -$176.0M | -$484.0M |
| Free cash margin | 138% | -74% | 1137% | -892% | -345% | -1467% |
| Cash | $173.4M | $148.0M | $206.0M | $127.0M | $150.0M | $222.0M |
| Long-term debt | — | — | — | $0 | $48.0M | $99.0M |
| Shareholders' equity | $502.0M | $842.0M | $657.0M | $462.0M | $485.0M | $631.0M |
| Shares outstanding | 65.11m | 70.80m | 72.90m | 75.50m | 92.20m | 125.30m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 21, 2024 | Annual ↗ | Dec 31, 2023 | 52d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 23, 2026 | Other events ↗ |
| Oct 21, 2026 | Results ↗ |
| Oct 20, 2026 | Other events ↗ |
| Aug 5, 2026 | Results ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 20, 2026 | Other events ↗ |
| Mar 23, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Dec 18, 2025 | Material agreement · New obligation ↗ |
| Dec 12, 2025 | Other events ↗ |
| Nov 3, 2025 | Other events ↗ |